



MARUTI SUZUKI

Geared to meet challenges; maintain BUY

Automobiles

26 April 2025

Milind Raginwar research@bobcaps.in

Adverse overall cost inflation also impacts EBITDA margin (at 10.5%) Tweak EBITDA factoring in mild volume impact. We continue to value

MSIL at 25x P/E with revised TP of Rs 13,899 (Rs 13,806). Maintain BUY

Q4FY25 revenue growth was 6% each YoY/QoQ, backed by the mix of

steady volume growth and supported by realisation gains YoY

Mild commodity costs inflation hit gross margin by 40bps YoY.

Topline steady; volume and realisations key drivers: MSIL's Q4FY25 revenue grew by a steady 6% each YoY/QoQ at ~Rs 407bn, backed by a mix of realisation and volume gains. Volume gains of 4% were backed by 3% YoY realisation gains, despite the adverse product mix (down 1% QoQ). Contribution from the high-end UV segment was ~37%, up from 36% YoY (down from 39.7% QoQ); exports contribution was higher at ~14.1% in Q4FY25, up from 13.5% YoY (flat Q3FY25). Average blended realisation/vehicle was Rs 672k.

Operating margin withers on adverse commodity and overall cost inflation: Raw material cost (inventory adjusted) rose by ~7%/6% YoY/QoQ and RM as percentage of sales inflated to ~71.9% versus 71.4% in Q4FY24, hit by the impact of higher RM cost (71.6% in 3QFY25). Hence, gross margins fell by ~40bps YoY to ~28.1% vs 28.6%/28.4% YoY/QoQ. Further, QoQ adverse impact of new Kharkoda plant overheads (30bps), adverse product mix (40bps), higher promo expenses (30bps, driven by Bharat Mobility Show, e-Vitara unveil etc.) and other expenses (90bps due to lumpy/seasonal costs like CSR, repairs, digitalisation, R&D) collectively impacted EBITDA margins to 10.5% down ~120bps/110bps YoY/QoQ.

Capacity expansion plans: The plant in Kharkoda was commissioned in Q4FY25. MSIL has signed an MoU with the Gujarat government to set up a 1mn unit plant by FY29 and has earmarked a capex of Rs 350bn. MSIL launched 2 new models in FY25 and plans to launch EV Grand Vitara and an SUV in FY26.

Tweak estimates, maintain BUY: We tweak our FY26E/FY27E EBITDA by -6%/-2% due to a slow demand revival, continued adverse mix in FY26 and tempered by additional cost impact. Our 3Y Revenue/ EBITDA/PAT CAGR is healthy at 10%/13%/11%; gross margin assumptions hover at ~30% with EBITDA margin of ~12% over FY25E-FY27E. We estimate the growth outlook backed by MSIL's focus on premiumisation, healthy capex and thrust on electric vehicles (average of 1 EV launch till FY30). Recent revival in rural affordability only augurs well for MSIL. We maintain BUY as we continue to value MSIL at 25x P/E 1YF earnings (on par with its 10Y average), with a revised TP of Rs 13,899 (Rs 13,806). Key changes

	Target	Rating	
Ticke	er/Price	MSIL IN/Rs 11,698	
Mark	et cap	US\$ 41.4bn	
Free	float	44%	
3M A	DV	US\$ 59.6mn	
52wk	high/low	Rs 13,680/Rs 10,725	
Prom	oter/FPI/DII	56%/23%/16%	

Source: NSE | Price as of 25 Apr 2025

Key financials

FY25P	FY26E	FY27E
15,19,001	16,80,387	18,61,196
1,77,852	2,06,046	2,36,206
1,39,552	1,59,150	1,78,360
443.9	506.2	567.3
443.9	512.0	573.0
14.9	15.1	15.1
26.4	23.1	20.6
20.0	17.1	15.0
5.6	14.0	12.1
	15,19,001 1,77,852 1,39,552 443.9 443.9 14.9 26.4 20.0	15,19,001 16,80,387 1,77,852 2,06,046 1,39,552 1,59,150 443.9 506.2 443.9 512.0 14.9 15.1 26.4 23.1 20.0 17.1

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE





Fig 1 – Earnings call highlights

Parameter	Q4FY25	Q3FY25	Our view
Volumes	In Q4FY25, MSIL sold 604.6K units, up 3.5% YoY. Domestic sales grew 2.8% to 519.5k units, and exports rose 8.1% to 85.1k units. Retail sales (4.2% gain YoY) outpaced wholesale, boosting retail market share marginally. Total sales of 2.23 mn units, up 4.6% YoY, driven by 2.7% domestic growth and 17.5% export growth. Rural markets outperformed urban markets in Q4 and FY25.	MSIL sold 566.2k vehicles in Q3FY25 (volume grew 4.6%/13% QoQ/YoY). MSIL sold 466.9k units in the domestic market, up 0.69%/8.7% QoQ/YoY. MSIL grew at 3.5% at retail level in 9MFY25 and expects similar growth in Q4FY25. MSIL observed rural markets doing better than urban markets with a continuing trend of upper segments doing better than lower segments.	Retail sales at 4.2% is likely to continue in the short term. Further, the new capacity at Kharkhoda will aid volume as capacity utillisation improves. Better export sales offset lower volume revival in domestic markets.
Margins	Operating profit margin fell to 8.7% from 10% in Q3FY25, due to adverse factors: New Kharkoda plant overheads/depreciation (30bps), steel commodity costs (20bps), adverse product mix (40bps), higher ad expenses (30bps, driven by Bharat Mobility Show, e-Vitara unveil, IPL), and other expenses (90bps, due to lumpy/seasonal costs like CSR, repairs, digitalization, R&D) However, there were positives: lower sales promotion expenses (40bps), favourable operating leverage (40bps), and forex gains (20bps, accounted in non-operating income due to hedging).	In Q3FY25 operating profit margin came down to 10%, vs 10.3% QoQ, as sales promotion expense was higher by 20bps QoQ and higher discounts were provided. There was additional advertisement expense on account of new launches. Forex movement was adverse by 20bps in Q3FY25 due to unfavourable Yen. Adverse expenses offset to some extent by favourable commodity prices (40bps) and operating leverage (30bps).	Mild reversal in commodity prices was offset by positive forex impact. One-time impact of new plant overheads will offset over the period. Promo expenses, too, will reverse in the short term.
Discounts	MSIL has announced two price hikes to offset steel cost pressures, although impact was not fully translated in the quarter.	Discounts extended per vehicle for Q3FY25 was Rs 30.99k vs Rs 29.3k in Q2FY25. MSIL recently announced a 30bps price hike of net sales to cover inflationary pressures.	Commodity price hikes pass through in the market twice help reduce pressure on margins —very encouraging for MSIL in a competitive market.
Supply	CNG share slightly declined to 33.7% from 36.1% in Q3FY25, but remained a significant portion of sales, supported by robust supply of 14 CNG models.	In Q3FY25, one in three vehicles sold in the domestic market was a CNG vehicle.	Adverse product mix did impact margins. However, the launch of EV and variants in the ICE segment implies no major impediment to growth.
Commodities	Steel prices had an impact on margins (20 bps), with safeguard taxes on steel imports mentioned. MSIL's imports exceed the minimum import price threshold, avoiding a direct impact while keeping an eye on domestic steel price hikes.	Margins have narrowed due to increase in advertisement and promotional expenses and unfavourable forex rate. However, adverse expenses were offset to some extent by favourable commodity prices (40bps) and operating leverage (30bps).	Some negative surprises were expected due to commodity cost inflation in the near term, which were reflected in Q4 gross margin decline for MSIL. However, pass-through impact will be reflected in Q1FY26
Capacity	Kharkoda Phase 1 (250k units per year) began commercial production in March 2025. Initial overheads/depreciation reduced margins by 30bps, but production ramp-up will normalise costs. Manesar facility has reached the 10 mn-unit milestone.	Kharkoda plant is on track for an additional 0.3mn units of capacity and will be commissioned in Q4FY25.	Capacity expansion is key for growth and is being addressed by management. MSIL's focus on the EV segment is a step in the right direction.

MARUTI SUZUKI



Parameter	Q4FY25	Q3FY25	Our view
Exports	Exports increased 8.1% YoY to 85,089 units, with MSIL accounting for 48.4% of India's PV export market. In FY25, exports increased by 17.5% to 332k units. Furthermore, the company expects exports to grow at 20% in FY26.	Sales volume in the export market in Q3FY25 was 99.2k, up 28%/38% QoQ/YoY. Revenue generated in Q3FY25 through exports was Rs 65bn. Major markets for MSIL's exports include Africa, LATAM, Middle East and ASEAN countries. MSIL had a 50% share of India's total passenger vehicle exports in Q3FY25.	Exports still form a relatively small proportion of the topline. Steady exports demand will aid further revenue growth. In a relatively slower domestic growth pace, focus on exports especially with EV launches will help volume growth
Electric Vehicles	MSIL's first electric SUV e-Vitara was unveiled and another SUV is in pipeline for this year. The company's HeartTech platform will be the base for the upcoming SUV.	MSIL unveiled its first e-SUV, the e-Vitara at the Bharat Mobility Global Expo 2025. It comes with efficient battery pack to deliver 500km for 61kwh in a single charge. E-Vitara will have OEM sales and exports to about 100 countries. MSIL is preparing about 1,500 EV-enabled service workshops covering 1000+ cities with specially trained manpower and equipment to address all EV-related support	This is in line with the company's long-term guidance of launching EVs by FY25- end. Strong focus on EV launches only augur well for the overall growth.
Other key points	At end-Q4FY25, the stock was of 28 days and has normalised due to higher wholesale sales. CAFE norms are under discussion and are likely to be finalized in 1-2 months. Hybrid adoption increased in FY25 due to favorable customer reaction and supportive state policies. MSIL introduced high-voltage courses for hybrid and EV serviceability.	MSIL had a stock of only about 9 days by December end. Maruti Suzuki Dzire clocked 3mn production milestone in Dec'24. Board approval received on 29 January 2025 for amalgamation of Suzuki Motor Gujarat (SMG) with MSIL.	Inventory concerns were only for the short term; on an average no major concerns. MSIL is confident of a pass through of regulatory price hikes, thus having a minimal impact on margins.
Source: Company, ROBCA	Suzuki Motor Gujarat (SMG) amalgamation with MSIL effective April 1, 2025, subject to regulatory approval.		

Source: Company, BOBCAPS Research



(Rs mn)	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)	Q4FY25E
Volume	6,04,635	5,84,031	3.5	5,66,213	6.8	6,04,635
Avg. Realisation per Vehicle	6,72,700	6,54,672	2.8	6,79,817	(1.0)	6,73,018
Net Revenues	4,06,738	3,82,349	6.4	3,84,921	5.7	4,06,931
Total Income (A)	4,06,738	3,82,349	6.4	3,84,921	5.7	4,06,931
Operating Expenses						
Raw materials consumed	2,92,353	2,72,884	7.1	2,75,567	6.1	2,92,178
Employee Expenses	15,691	13,662	14.9	15,415	1.8	15,667
Other Expenses	56,047	48,953	14.5	49,228	13.9	51,884
Total Expenditure (B)	3,64,091	3,35,499	8.5	3,40,210	7.0	3,59,729
EBITDA (A-B)	42,647	46,850	(9.0)	44,711	(4.6)	47,202
Other Income	14,466	11,180	29.4	9,850	46.9	9,910
Depreciation	8,724	7,290	19.7	8,050	8.4	8,110
EBIT	48,389	50,740	(4.6)	46,511	4.0	49,002
Finance Costs	472	762	(38.1)	484	(2.5)	494
PBT after excep items	47,917	49,978	(4.1)	46,027	4.1	48,508
Tax expense	10,806	11,200	(3.5)	10,769	0.3	11,157
Reported PAT	37,111	38,778	(4.3)	35,258	5.3	37,351
Adjusted PAT	37,111	38,778	(4.3)	35,258	5.3	37,351
EPS (Rs)	122.9	128.4	(4.3)	116.7	5.3	123.7
Key Ratios (%)			(bps)		(bps)	
Gross Margin	28.1	28.6	(50.7)	28.4	(28.7)	28.2
EBITDA Margin	10.5	12.3	(176.8)	11.6	(113.1)	11.6
EBIT Margin	11.9	13.3	(137.4)	12.1	(18.6)	12.0
PBT Margin	11.8	13.1	(129.1)	12.0	(17.7)	11.9
Tax Rate	22.6	22.4	14.2	23.4	(84.6)	23.0
Adj PAT Margin	9.1	10.1	(101.8)	9.2	(3.6)	9.2

Fig 2 – Quarterly performance (Standalone)

Source: Company, BOBCAPS Research



Valuation methodology

We tweak our FY26E/FY27E EBITDA by -6%/-2% due to a slow demand revival, continued adverse mix in FY26 and tempered by additional cost impact. Our 3Y Revenue/ EBITDA/PAT CAGR is healthy at 10%/13%/11%; gross margin assumptions hover at ~30% with EBITDA margin of ~12% over FY25E-FY27E. We estimate growth outlook backed by MSIL's focus on premiumisation, healthy capex and thrust on EVs (average of 1 EV launch till FY30). Recent revival in rural affordability only augurs well for MSIL.

We maintain BUY as we continue to value MSIL at 25x P/E 1YF earnings (on par with its 10Y average), with a revised TP of Rs 13,899 (Rs 13,806).

(Do ma)	Ne	w	O	d	Change	: (%)
(Rs mn)	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Revenue	16,80,387	18,61,196	18,16,497	20,64,517	(7.5)	(9.8)
EBITDA	2,06,046	2,36,206	2,18,901	2,40,322	(5.9)	(1.7)
Adj PAT	1,59,150	1,78,360	1,58,419	1,74,067	0.5	2.5
Adj EPS (Rs)	506.2	567.3	503.9	553.6	0.5	2.5

Fig 3 – Revised estimates

Source: BOBCAPS Research

Fig 4 – Key assumptions

Parameter	FY24	FY25E	FY26E	FY27E
Volume (nos)	20,64,472	22,42,089	23,54,194	25,07,216
ASP (Rs)	6,66,465	6,99,789	7,13,784	7,42,336
Revenues (Rs mn)	14,09,326	15,19,001	16,80,387	18,61,196
EBITDA (Rs mn)	1,64,011	1,77,852	2,06,046	2,36,206
Operating margin (%)	11.6	11.7	12.3	12.7
Adjusted Net Profit (Rs mn)	1,32,094	1,39,552	1,59,150	1,78,360
Adjusted EPS (Rs)	420	444	506	567

Source: Company, BOBCAPS Research

Fig 5 – Peer comparison

Company	Ticker	Rating	Target Price	EPS	(Rs)	ROE	: (%)
Company	TICKET	Kaung	(Rs)	FY26E	FY27E	FY25E	FY26E
Maruti Suzuki	MSIL IN	BUY	13,899	506	567	16.0	16.0
Mahindra & Mahindra	MM IN	BUY	3,689	127.1	142.5	22.3	20.8

Source: BOBCAPS Research



Fig 6 – P/E band: We value MSIL at 25x 1YF EPS





Fig 7 – P/E 1F: Valuation is at mean average



Source: Company, Bloomberg, BOBCAPS Research

Key risks

Key downside risks to our estimates:

- Intense competitive pressure leading to higher discounts/price cuts
- Commodity inflation gaining pace faster than expected
- Delays in model launches in various segments, including CNG and EVs.



Financials

Income Statement					
Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25P	FY26E	FY27E
Total revenue	11,75,229	14,09,326	15,19,001	16,80,387	18,61,196
EBITDA	1,10,077	1,64,011	1,77,852	2,06,046	2,36,206
Depreciation	28,233	30,223	31,593	35,840	40,040
EBIT	1,03,457	1,72,336	1,93,763	2,21,593	2,48,030
Net interest inc./(exp.)	(1,866)	(1,932)	(1,931)	(2,075)	(2,017)
Other inc./(exp.)	21,613	38,548	47,504	51,387	51,864
Exceptional items	0	0	0	0	0
EBT	1,01,591	1,70,404	1,91,832	2,19,518	2,46,013
Income taxes	21,099	38,310	52,280	60,367	67,654
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	80,492	1,32,094	1,39,552	1,59,150	1,78,360
Adjustments	0	0	0	0	0
Adjusted net profit	80,492	1,32,094	1,39,552	1,59,150	1,78,360

Balance Sheet					
Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25P	FY26E	FY27E
Accounts payables	1,51,982	1,88,798	1,98,993	1,99,308	2,33,421
Other current liabilities	27,163	27,914	53,565	62,544	55,207
Provisions	10,500	13,514	15,683	3,957	4,352
Debt funds	38,322	32,802	34,583	24,715	17,558
Other liabilities	0	0	0	0	0
Equity capital	1,510	1,572	1,572	1,572	1,572
Reserves & surplus	6,02,311	8,38,249	9,34,513	10,50,800	11,76,489
Shareholders' fund	6,03,821	8,39,821	9,36,085	10,52,372	11,78,061
Total liab. and equities	8,31,788	11,02,849	12,38,908	13,42,896	14,88,599
Cash and cash eq.	377	4,600	4,464	3,366	2,081
Accounts receivables	32,958	46,013	39,225	42,850	47,461
Inventories	42,838	41,196	62,760	68,056	75,378
Other current assets	55,324	65,019	86,181	71,051	76,565
Investments	4,77,564	6,85,137	7,45,063	8,36,063	9,37,063
Net fixed assets	1,78,938	1,87,258	2,27,086	2,51,246	2,71,206
CWIP	28,081	63,034	77,575	75,000	85,000
Intangible assets	0	0	0	0	0
Deferred tax assets, net	3,411	1,124	(12,911)	(14,202)	(15,622)
Other assets	12,296	9,467	9,467	9,467	9,467
Total assets	8,31,787	11,02,848	12,38,909	13,42,896	14,88,599

Cash Flows

FY23A	FY24A	FY25P	EVOOR	
	112-01	FIZOF	FY26E	FY27E
91,473	1,43,761	1,23,788	1,45,305	1,74,242
(68,785)	(73,496)	(85,962)	(57,425)	(70,000)
(69,931)	(2,07,573)	(59,926)	(91,000)	(1,01,000)
21,613	38,548	47,504	51,387	51,864
(1,17,103)	(2,42,521)	(98,384)	(97,038)	(1,19,136)
0	1,28,405	0	0	0
12,322	(5,520)	1,781	(9,867)	(7,158)
(1,866)	(1,932)	(1,931)	(2,075)	(2,017)
(18,125)	(27,187)	(42,444)	(48,386)	(55,160)
(1,384)	2,287	14,035	1,291	1,420
(9,053)	96,053	(28,559)	(59,037)	(62,915)
(34,683)	(2,707)	(3,155)	(10,770)	(7,809)
377	4,600	4,464	3,366	2,081
	(68,785) (69,931) 21,613 (1,17,103) 0 12,322 (1,866) (18,125) (1,384) (9,053) (34,683)	(68,785) (73,496) (69,931) (2,07,573) 21,613 38,548 (1,17,103) (2,42,521) 0 1,28,405 12,322 (5,520) (1,866) (1,932) (18,125) (27,187) (1,384) 2,287 (9,053) 96,053 (34,683) (2,707)	(68,785) (73,496) (85,962) (69,931) (2,07,573) (59,926) 21,613 38,548 47,504 (1,17,103) (2,42,521) (98,384) 0 1,28,405 0 12,322 (5,520) 1,781 (1,866) (1,932) (1,931) (18,125) (27,187) (42,444) (1,384) 2,287 14,035 (9,053) 96,053 (28,559) (34,683) (2,707) (3,155)	(68,785) (73,496) (85,962) (57,425) (69,931) (2,07,573) (59,926) (91,000) 21,613 38,548 47,504 51,387 (1,17,103) (2,42,521) (98,384) (97,038) 0 1,28,405 0 0 12,322 (5,520) 1,781 (9,867) (1,866) (1,932) (1,931) (2,075) (18,125) (27,187) (42,444) (48,386) (1,384) 2,287 14,035 1,291 (9,053) 96,053 (28,559) (59,037) (34,683) (2,707) (3,155) (10,770)

FY27 567. 175. 3,747. 15. 20. 3. FY27 72. 99. 13.
567. 175. 3,747. FY27 1. 15. 20. 3. FY27 72. 99.
175. 3,747. FY27 1. 15. 20. 3. FY27 72. 99.
3,747. FY27 1. 15. 20. 3. FY27 72. 99.
FY27 1. 15. 20. 3. FY27 72. 99.
1. 15. 20. 3. FY27 72. 99.
1. 15. 20. 3. FY27 72. 99.
1. 15. 20. 3. FY27 72. 99.
15. 20. 3. FY27 72. 99.
20. 3. FY27 72. 99.
3. FY27 72. 99.
FY27 72. 99.
72. 99.
72. 99.
99.
163.
1.
16.
EV07
FY27
10
10.
14.
12.
10
12.
13.
9.
15.
15.
1
1 6
6

 Adjusted debt/equity
 0.1
 0.0

 Source: Company, BOBCAPS Research | Note: TA = Total Assets

Net interest coverage ratio

(55.4)

(89.2)

(100.3)

0.0

(106.8)

0.0

(123.0)

0.0



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited** Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051** SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025** Brand Name: **BOBCAPS** Trade Name: www.barodaetrade.com



Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): MARUTI SUZUKI (MSIL IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

MARUTI SUZUKI



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or merchan banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.